Drug discovery: selecting the optimal approach

Drug Discovery Today

Volumn 11, Issue 9-10, 2006, Pages 465-472

  Sams Dodd, Frank ^a  

^a Les Algorithmes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; NEW DRUG; SEROTONIN UPTAKE INHIBITOR; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; ANALYTIC METHOD; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CELL FREE SYSTEM; COMPARATIVE STUDY; DEPRESSION; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHYSIOLOGY; REVIEW; TRANSGENIC MOUSE; VALIDATION PROCESS;

DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MICRODIALYSIS; MODELS, ANIMAL; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 33646517064     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.03.015     Document Type: Review

References (35)

1. Van den Haak et al. (2004) Industry Success Rates 2004. CMR Report 04-234R
2. Accenture and CMR International. Rethinking Innovation in Pharmaceutical R&D (2005), Accenture and CMR International
3. FDA (2004) Innovation and stagnation: challenge and opportunity on the critical path to new medical products. FDA white paper
4. Horrobin D.F. Opinion: Modern biomedical research: an internally self-consistent universe with little contact with medical reality?. Nat. Rev. Drug Discov. 2 (2003) 151-154
5. Butcher E.C. Can cell systems biology rescue drug discovery?. Nat. Rev. Drug Discov. 4 (2005) 461-467
6. Weisbach J.A., and Moos W.H. Diagnosing the decline of major pharmaceutical research laboratories; a prescription for drug companies. Drug Dev. Res. 34 (1995) 243-259
7. Drews J., and Ryser S. Innovation deficits in the pharmaceutical industry. Drug Inform. J. 30 (1996) 97-108
8. Brown D., and Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discov. Today 8 (2003) 1067-1077
9. Arlington S., et al. Pharma 2010 - the threshold of innovation (2004), IBM
10. Sams-Dodd F. Target based drug discovery: is something wrong?. Drug Discov. Today 10 (2005) 139-147
11. Liu H., et al. Structure-based discovery of potassium channel blockers from natural products: Virtual screening and electrophysiological assay testing. Chem. Biol. 10 (2003) 1103-1113
12. Williams G.P. Advances in high throughput screening. Drug Discov. Today 9 (2004) 515-516
13. Fischer H.P., and Heyse S. From targets to leads: the importance of advanced data analysis for decision support in drug discovery. Curr. Opin. Drug Discov. Devel. 8 (2005) 334-346
14. Vaswani M., et al. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 85-102
15. Beher D., et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target?-secretase at a novel site: Evidence for an allosteric mechanism. J. Biol. Chem. 279 (2004) 43419-43426
16. In: Hirsh S.R., and Weinberger D.R. (Eds). Schizophrenia (1995), Blackwell Science
17. Ichikawa J., et al. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: Role of 5-HT(1A) receptor agonism. Brain Res. 1049 (2005) 182-190
18. Dransfield M.T., and Bailey W.C. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. Expert Opin. Pharmacother. 5 (2004) 1815-1826
19. Sams-Dodd, F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov. Today (in press)
20. Morris H.R., et al. Genome-wide analysis of the parkinsonism-dementia complex of Guam. Arch. Neurol. 61 (2004) 1889-1897
21. Forman M.S., et al. Tau and alpha-synuclein pathology in amygdala of parkinsonism-dementia complex patients of Guam. Am. J. Pathol. 160 (2002) 1725-1731
22. Shoji M., et al. A proposal for diagnostic and clinical assessment criteria for Alzheimer's disease. Rinsho Shinkeigaku 45 (2005) 128-137
23. Stokin G.B., et al. Axonopathy an Transport Deficits Early in the Pathogenesis of Alzheimer's Disease. Science 307 (2005) 1282-1288
24. Billings L.M., et al. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
25. Colton C.A., et al. NO2 regulation of Tau hyperphosphyrylation in a mouse model of AD. 7'th International Conference AD/PD 2005 (2005) 108
26. Yanovski S.Z., and Yanovski J.A. Obesity. N. Engl. J. Med. 346 (2002) 591-602
27. Veniant M.M., and LeBel C.P. Leptin: From Animals to Humans. Curr. Pharm. Des. 9 (2003) 811-818
28. Butcher E.C., et al. Systems biology in drug discovery. Nat. Biotechnol. 22 (2004) 1253-1259
29. Kilarski W.W., et al. An ex vivo model for functional studies of myofibroblasts. Lab. Invest. 85 (2005) 643-654
30. Granas C., et al. High content screening for G protein-coupled receptors using cell-based protein translocation assays. Comb. Chem. High Throughput Screen. 8 (2005) 301-309
31. Langenau D.M., and Zon L.I. The Zebrafish: A new model of T-cell and thymic development. Nat. Rev. Immunol. 5 (2005) 307-317
32. Horrocks C., et al. Human cell systems for drug discovery. Curr. Opin. Drug Discov. Devel. 6 (2003) 570-575
33. Daniele N., et al. Conditionally immortalized cell lines as model systems for high-throughput biology in drug discovery. Biochem. Soc. Trans. 30 (2002) 800-802
34. Barnes K.E. Human tissue in drug discovery: promises and pitfalls. Drug Discov. Today 9 (2004) 55
35. Sams-Dodd F. Optimising the discovery organization for innovation. Drug Discov. Today 10 (2005) 1049-1056